Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RenovoRx (RNXT) EBITDA (2024 - 2025)

RenovoRx (RNXT) has disclosed EBITDA for 2 consecutive years, with -$3.5 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 33.81% to -$3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.5 million through Dec 2025, down 21.16% year-over-year, with the annual reading at -$11.2 million for FY2025, 26.71% down from the prior year.
  • EBITDA hit -$3.5 million in Q4 2025 for RenovoRx, down from -$3.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.4 million in Q2 2024 to a low of -$3.5 million in Q4 2025.